How much funding has Connect Biopharma raised?

Connect Biopharma has raised $215.2M in total funding, most recently a Corporate Round.

Who are Connect Biopharma's investors?

Connect Biopharma's investors include Qiming VP, Panacea Venture, Cowin Venture, Northern Light Ventures, Boxer Capital, HBM Healthcare Investments.

When was Connect Biopharma founded?

Connect Biopharma was founded in 2012.

Where is Connect Biopharma headquartered?

Connect Biopharma is headquartered in San Diego, California, United States.

What industry is Connect Biopharma in?

Connect Biopharma operates in Biotech, Healthcare, Immunology.

How many employees does Connect Biopharma have?

Connect Biopharma has 51-200 employees.

Connect Biopharma

IPO

Aspiring to Improve Patients' Lives

Public · San Diego, United States · Founded 2012 · $215.2M raised

Biotech

Healthcare

Immunology

Headquarters: San Diego, California
Employees: 51–200
Founded: 2012
Business Model: B2B
Website: connectbiopharma.com

Total Funding: $215.2M
Last Round: $20.2M Corporate RoundMar 2026
Rounds: 4
Type: Public

About

Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart (CBP-201), a next-generation, potentially best-in-class monoclonal antibody designed to target interleukin-4 receptor alpha (IL-4Rα). Rademikibart is being evaluated in global Phase 2 clinical studies (Seabreeze STAT) for the treatment of acute exacerbations of asthma and COPD — conditions with significant unmet medical need. Founded in 2012 with operations in San Diego and China, Connect Biopharma trades on Nasdaq under the ticker CNTB. The company's scientific approach centers on next-generation biologics designed to redefine treatment landscapes for patients with serious inflammatory diseases.

Summary

Connect Biopharma is a Biotech company based in San Diego, United States, founded in 2012. It has raised $215.2M in total across 4 rounds, most recently a $20.2M Corporate Round round in Mar 2026. Investors include Qiming VP, Panacea Venture and Cowin Venture.

LinkedIn X (Twitter)